Related Experiment Video
Updated: Feb 13, 2026
12:40
Isolation and Expansion of Mesenchymal Stem/Stromal Cells Derived from Human Placenta Tissue
Published on: June 6, 2016
38.2K
Placenta-Derived Cells for Acute Brain Injury
Francesca Pischiutta1, Eliana Sammali1,2, Ornella Parolini3,4
11 Department of Neuroscience, Laboratory of Acute Brain Injury and Therapeutic Strategies, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Cell Transplantation
|March 23, 2018
Summary
Placenta-derived stem cells show promise for treating acute brain injuries like stroke and traumatic brain injury (TBI). These cells and their secretome offer a potential new therapeutic strategy for brain repair and functional recovery.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Cell Biology
Background:
- Acute brain injury, including stroke and traumatic brain injury (TBI), is a major global cause of death and disability.
- Current neuroprotective treatments for acute brain injury are limited, necessitating novel therapeutic approaches.
- The complex pathology of brain injury requires interventions targeting multiple mechanisms for effective treatment.
Purpose of the Study:
- To review the evidence supporting placenta-derived stem cells (PDSCs) for acute brain injury.
- To explore strategies for enhancing PDSC therapeutic potential.
- To examine the role of the PDSC secretome as a cell-free therapeutic option.
Main Methods:
- Systematic review of experimental studies on PDSCs in stroke and TBI models.
- Analysis of cell engineering techniques to improve PDSC efficacy.
- Characterization of PDSC secretome components and their functions.
Main Results:
- PDSCs demonstrate significant neuroprotective and regenerative effects in experimental models of stroke and TBI.
- Cell engineering strategies can enhance PDSC survival, differentiation, and therapeutic outcomes.
- The PDSC secretome contains bioactive molecules that mediate beneficial effects, offering a cell-free therapeutic alternative.
Conclusions:
- Placenta-derived stem cells and their secretome represent a promising therapeutic avenue for acute brain injury.
- Further research and clinical trials are warranted to translate these findings into effective patient treatments.
- PDSCs offer advantages in terms of accessibility and ethical considerations for brain injury therapies.
Related Concept Videos
01:22Acute Kidney Injury I: Introduction
804
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
804
01:29Acute Kidney Injury II: Pathophysiology
1.2K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.2K
01:22Acute Kidney Injury VI: Nursing Management
492
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
492
01:20Acute Kidney Injury V: Interprofessional Care
365
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
365
01:29Acute Kidney Injury III: Clinical Manifestations
984
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
984
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
346
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
346